At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SCNX Scienture Holdings, Inc.
Post-Mkt 02-04 17:35:04 EST
0.4607
+0.0039
+0.85%
盘后0.4600
-0.0007-0.15%
17:25 EST
High0.4660Low0.4343Vol504.55K
Open0.4660D1 Closing0.4568Amplitude6.94%
Mkt Cap18.72MTradable Cap15.66MTotal Shares40.63M
T/O227.43KT/O Rate1.48%Tradable Shares33.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney
Reuters  ·  02-03 22:17
BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney
BUZZ-Scienture jumps after expanding access to hypertension drug
Reuters  ·  02-03 21:17
BUZZ-Scienture jumps after expanding access to hypertension drug
Scienture Holdings Reaffirms Q1 2026 Growth Outlook
Reuters  ·  02-03 21:05
Scienture Holdings Reaffirms Q1 2026 Growth Outlook
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
GlobeNewswire  ·  02-03 21:05
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
BUZZ-Scienture Holdings jumps after U.S. FDA clears opioid overdose spray
Reuters  ·  01-14
BUZZ-Scienture Holdings jumps after U.S. FDA clears opioid overdose spray
Scienture Announces Issuance of Orange Book-Listable Patent Covering Rezenopy™, the Highest Dosage Naloxone Hcl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
THOMSON REUTERS  ·  01-14
Scienture Announces Issuance of Orange Book-Listable Patent Covering Rezenopy™, the Highest Dosage Naloxone Hcl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment
Benzinga_recent_news  ·  01-14
EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment
BRIEF-Scienture Provides Update On The Commercial Launch Of Rezenopy
Reuters  ·  2025-12-22
BRIEF-Scienture Provides Update On The Commercial Launch Of Rezenopy
Scienture Holdings Launches High-Strength REZENOPY Naloxone Nasal Spray in U.S. Market
Reuters  ·  2025-12-22
Scienture Holdings Launches High-Strength REZENOPY Naloxone Nasal Spray in U.S. Market
Scienture Holdings Inc - Rezenopy Expected Commercially Available Early Q2 2026
THOMSON REUTERS  ·  2025-12-22
Scienture Holdings Inc - Rezenopy Expected Commercially Available Early Q2 2026
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
GlobeNewswire  ·  2025-12-22
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
Why Is Scienture Stock Gaining Today?
Benzinga_recent_news  ·  2025-12-10
Why Is Scienture Stock Gaining Today?
BRIEF-SCIENTURE And BlinkRx Announce Strategic Collaboration To Expand Patient Access To Arbli, The First FDA-Approved Ready-To-Use Oral Suspension Of Losartan Potassium
Reuters  ·  2025-12-10
BRIEF-SCIENTURE And BlinkRx Announce Strategic Collaboration To Expand Patient Access To Arbli, The First FDA-Approved Ready-To-Use Oral Suspension Of Losartan Potassium
Scienture and Blinkrx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
THOMSON REUTERS  ·  2025-12-10
Scienture and Blinkrx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
Scienture Holdings Inc - Arbli Expected on Blinkrx Platform in Q1 2026
THOMSON REUTERS  ·  2025-12-10
Scienture Holdings Inc - Arbli Expected on Blinkrx Platform in Q1 2026
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
GlobeNewswire  ·  2025-12-02
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
Scienture Holdings Inc. held annual shareholder meeting
Reuters  ·  2025-11-15
Scienture Holdings Inc. held annual shareholder meeting
Scienture reports Q3 EPS (19c) vs. ($1.34) last year
TIPRANKS  ·  2025-11-13
Scienture reports Q3 EPS (19c) vs. ($1.34) last year
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
GlobeNewswire  ·  2025-11-13
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction
Benzinga  ·  2025-11-13
EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction

Introduction

Company Name.
Scienture Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Lutz, Florida.
Issue price:
--